We have worked with eleven veterinary groups in the 5-to-15 location band over the past four years, and the pattern is consistent enough that I now describe it as a phase rather than a set of decisions. The group has proven the unit economics in one or two locations. It has done two or three acquisitions on instinct and seller-relationship. And now the founder is the finance function — for cash, for the next deal, for the lender conversation, for the doctor compensation model — and the system is bending in three named places. The macro is not friendly underneath this. Ackerman Group has tracked fourteen consecutive quarters of same-store visit decline through 2025; Encore Vet's 2025 review puts visits down roughly 2% with revenue held up by ACT growth of 6–10%; AVMA has more than half of owners reporting they skipped needed vet care on cost. The fractional CFO seat in this band is operating-finance, not capital-markets finance — at least until the group crosses into platform scale. Here is the working playbook.
01 What bends between location three and ten
Three things bend, almost always in this order. First, cash visibility — the founder loses the ability to know, on any given Wednesday, what is in the bank net of next week's payroll and the working-capital draw on the next acquisition. Second, individual-clinic visibility — the consolidated P&L still works, but the underperforming clinic that is dragging the group down stops being legible. Third, doctor compensation — the model that worked for the first three doctors does not survive a fourth and a fifth, and the founder is now hiring instead of buying.
None of these are finance problems in the technical sense. They are operating problems whose answers happen to live inside the finance function. That is the gap the fractional CFO fills, and the gap is wider in veterinary than in dental or medspa because the doctor compensation question and the cash-rhythm question both have an extra layer of complexity: the DVM labour market is structurally tight (AVMA reports a 0.7% unemployment rate among veterinarians in 2024, with Mars Veterinary Health and AVMA workforce models projecting a shortfall of 14,000–24,000 DVMs by 2030–2032), and same-store visit volume has been negative for fourteen consecutive quarters per Ackerman Group, meaning the topline is propped up by pricing in a way that the operator needs to see weekly, not monthly.
The right starting question for an engagement in this band is not "what does your P&L look like." It is: how often do you reconcile your bank, when did you last see a clean clinic-level P&L on the same day for all five (or eight, or twelve) locations, and do you have one harmonised doctor compensation model or are you running five different ones because you inherited five different seller agreements. Almost universally, the answer to the third question is the second number.
These are operating problems whose answers happen to live inside the finance function. The fractional CFO is filling an operating gap with finance discipline — not the other way around.
02 The new cash rhythm — weekly, not monthly
We move groups in this band off monthly cash reporting and onto a weekly 13-week forecast within the first 30 days. Two reasons. First, the next acquisition is sitting on the calendar 60–120 days out, and the founder needs to see — every Monday — whether the deal is still affordable against debt service, working-capital draw, and the integration cash hit in months two and three. Second, the working-capital cycle of a clinic group is short enough that weekly is the right cadence; monthly washes out the signal that the operator needs to see when same-store visits are running down 2% and ACT is the only thing holding revenue up.
The structural pieces are well established and worth naming. The cash accounts get consolidated into a HoldCo operating account with sub-accounts for payroll, taxes, and capex; clinic deposits sweep daily. AP runs weekly or biweekly from headquarters — clinics submit approvals, treasury controls timing. AR target is ≤1% of annual revenue per the Today's Veterinary Business and VHMA benchmarks; CareCredit and Scratchpay carry the financing, not the clinic balance sheet. Minimum cash reserve sits at 6–8 weeks of fixed costs (rent, FT payroll, debt service) per the PlotPath veterinary guidance — leaner groups run at one month of expenses with another half-month parked in a high-yield business savings account.
The 13-week forecast itself is not sophisticated. It is a sheet — columns are weeks, rows are inflows and outflows by clinic and corporate, prior-week actuals replace forecast every Friday, and conditional formatting flags any week that goes negative. The decision rules are explicit: one negative week pulls forward collections and pushes nonessential spend; two consecutive negative weeks freeze hiring, defer capex, and draw on the LOC. The whole document is two screens. Founders trust it because it is short, it updates on a known cadence, and it ties directly to the operating decisions they are about to make.
You do not need a sophisticated forecast at this stage. You need a forecast that the founder trusts enough to make Tuesday's decision on.
The scenario overlays come second — adding a DVM at clinic 4, modeling a 10% fee schedule increase, sizing the next LOI at the founder's price and at the stress price. These are layered into the same sheet, not built separately. The mental model is: one cash document, one finance forecast, one source of truth for "what do we know about the next thirteen weeks." Everything else is a tab inside it. Detailed structure and weekly cadence are documented in our 13-week cash flow template for multi-site healthcare at /blog/13-week-cash-flow-template-dso-multi-site-medical/ — the same framework runs cleanly across DSOs, medspas, and vet groups.
03 Clinic-level P&L that the doctors can read
Most pre-consolidator groups have a clinic-level P&L that an accountant can read and an operator cannot. We rebuild it. The version that survives this phase has six lines visible to the head doctor of each clinic: production, collections, doctor compensation, support staff, contribution after labour, and contribution after occupancy. The accounting can stay as it is in QuickBooks. The operating version sits on top.
Underneath the six-line operating view is the full P&L with the cost-line discipline that drives the diagnosis. COGS sits at 20–25% of revenue in a healthy small-animal GP — anything above 28–30% is a Vetcelerator-flagged red flag, almost always reading as either inventory shrink, drug-pricing creep, or mark-up discipline that drifted. DVM compensation runs 18–22% of revenue; non-DVM staff 22–28%; total staff costs 40–50%. Occupancy lands at 7–11% of revenue and starts constraining contribution above 12–13%. Clinic EBITDA before corporate overhead should clear 18–25% in a strong GP and 12–18% consolidated after central overhead. These benchmarks are well-documented in the Simmons, VHMA, and AAHA materials and they are the right reference band for a pre-consolidator group.
The single highest-ROI move inside the rebuild is separating DVM compensation from support-staff labour on the operating view. In nine of our eleven engagements, this is the change that surfaced the underperforming clinic the founder did not realise was underperforming. The total staff-cost line at 45% looks fine on a consolidated P&L; when you split it into "DVM 22% / support 23%" at clinic A versus "DVM 19% / support 28%" at clinic B, the operator immediately sees that clinic B is over-staffed on support and a re-mix conversation is on the table. The same is true with occupancy creep on a single bad lease — the cost only becomes legible when the line sits on the operating view next to its peer clinics.
The support-staff ratio piece
The corporate consolidators are running 3.5–4.5 support FTEs per DVM-FTE with at least one to two credentialed techs per DVM. Independent groups in the 5–15 band typically run 2.5–3.5 support FTEs per DVM and have a credentialed-tech gap. Closing that gap is one of the highest-ROI operating moves available and shows up directly in DVM productivity — CVMA data points to roughly $79k of additional revenue per DVM for each added RVT, and ~$122k of additional revenue per DVM when techs are paid above $21/hr versus at or below $15/hr. The fractional CFO's job is to name the gap on the operating P&L and size the payback before the founder approves the next hire.
Revenue per DVM-FTE is the single metric we anchor the engagement on. Common GP runs $800k–$1.3M per DVM-FTE; high-performing or corporatized groups run $1.2M–$1.5M+. The gap to the top quartile is almost always a mix of (1) ACT discipline, (2) diagnostics utilization, and (3) support-staff leverage. Provider productivity in DSO and multi-site medical contexts follows the same logic — we have written the longer methodology in /blog/provider-productivity-dso-single-metric/. The single-metric framing translates one-for-one to veterinary GP.
04 Doctor compensation — the model that survives consolidation
Half the deals in this band die in the first 90 days post-close on doctor compensation. The selling doctor's comp model rarely survives consolidation, and the harmonisation work has to be done before the LOI, not after the close. We have written about Day-1-to-100 integration risk for DSOs at /blog/dso-day-1-to-100-integration-playbook/ — the playbook reads identically for vet groups, with doctor comp as the single largest source of retention risk.
The three dominant comp models in the band today are straight salary, pure production (typically 20–23% of individual collected production), and ProSal (base + production true-up). AVMA and VetPartners commentary through 2024 shows the drift away from pure production toward ProSal for mid-career associates and salary + structured bonus for new grads. The fractional CFO's job is to land the group on one model — one definition of production, one true-up cadence (quarterly or annual), one explicit list of excluded revenue (retail, OTC, deep-discount write-off portion, wellness-plan revenue not attributable to a visit). The acquired doctor moves onto the harmonised model at close, usually with a one-year transition adjustment if the prior model paid materially differently.
The compensation levels themselves are not negotiable in the way they were five years ago. AVMA 2023–2024 data puts associate small-animal GP total comp at $130k–$150k median; competitive 2025–2026 offers in tight metros are landing at $150k–$190k for experienced associates and ER-heavy GPs. BLS reports the average DVM salary at roughly $136,000 in 2025. Owner-DVM clinical comp normalises at $180k–$220k for a $1.5M-revenue clinic in the Simmons valuation framework — and getting this number explicit on the operating P&L is what separates a defensible normalized EBITDA from a seller-credibility problem in diligence.
Why the comp model belongs to finance, not HR
In groups under fifteen locations, there is rarely a dedicated HR function — the practice manager handles people questions and the founder handles compensation. When the comp model is operating as a finance function (i.e., when it is fully documented, when the true-up math is in the model, and when the production definition is written down), the founder gets to step back from those conversations and the practice manager can run them at the clinic level. When the comp model lives in the founder's head, every doctor conversation escalates to the founder. The graduation point — when the engagement ends — is when the comp framework has been documented to the point that a new hire can be onboarded by the ops director without the founder in the room.
05 The next deal, sized honestly
The founder usually wants the next deal to be a stretch. The fractional CFO's job is to model the deal at two prices — the founder's price and a stress price 12% above it — and run both through the next twelve months of consolidated cash. The stress version is the one that decides whether the LOI gets signed at the founder's price or 8% below it. This is the conversation that pays for the engagement, often inside the first quarter.
The pricing context underneath the conversation matters. Most 5–15-location groups transacting in 2024–2025 are clearing 6–9x adjusted EBITDA as add-ons — Transitions Elite reports a 6–16x range for Q1 2025 vet deals across the full size spectrum, with the spread driven mostly by EBITDA scale and platform-readiness. The top quartile of 5–15-site groups (those with $3–5M+ EBITDA, professional management, regional density, and predictable wellness-plan revenue streams) clear at quasi-platform multiples of 10–14x; the bottom three quartiles, doctor-dependent and lighter on central infrastructure, clear at 5–8x. Sub-$2M EBITDA groups are priced as add-ons regardless of location count.
The deal structure piece matters as much as the headline multiple. Norms in this band are 50–80% cash at close, 10–30% rollover into the buyer's platform HoldCo, earnouts used selectively where growth is baked in or doctor retention is uncertain. A 7x with 80% cash at close is often a better deal than a 9x with heavy earnouts and 30%+ rollover — the comparison the fractional CFO needs to run for the seller, with the rollover modeled out at a credible 3-year exit assumption. The full read on multi-site healthcare M&A multiples in Q2 2026 is at /blog/multi-site-healthcare-ma-multiples-q2-2026/ — the methodology is consistent across dental, medical, and veterinary, with the vet-specific bands sitting at the higher end of the multi-site healthcare spread.
Doctor comp at acquisition
Half the deals in this band die in the first 90 days post-close on doctor compensation. The selling doctor's comp model rarely survives consolidation, and the fractional CFO needs to have the harmonised comp model ready before the LOI, not after the close. We size the doctor-retention hit at 8–15% of acquired EBITDA in the first twelve months if the comp transition is poorly managed, and at zero-to-3% when the harmonisation work is done pre-LOI. That single piece of work is usually worth the engagement fee on its own.
Real estate, separately
Real estate is the second deal underneath the deal. If the seller owns the clinic building, the choice is to sell to the buyer's RE arm or REIT, or keep and lease back at a fair-market 10–15-year lease with renewal options. Well-structured leases support higher EBITDA multiples because they reduce uncertainty for the buyer; the fractional CFO needs to model both paths and walk the founder through the after-tax economics with a clear three-scenario summary. The Day-1-to-100 acquisition framework at /blog/first-100-days-post-acquisition-multi-site-healthcare/ covers the integration sequencing for both paths.
06 The lender conversation, and the credit story
Around five clinics, the group typically outgrows its initial banking relationship. The original community-bank operating line that funded the first two acquisitions does not scale to fund acquisitions four through eight, and the group needs to either (a) build a relationship with a regional bank with healthcare-vertical capability, or (b) bring in a private-credit relationship that will fund unitranche debt against the consolidated EBITDA. The fractional CFO is the person who sits in the lender-pitch room and runs the data room — almost universally, the founder has never built a credit memo for an outside lender before, and the founder's natural framing (relationship, growth story, seller-financing optionality) is not the framing that gets credit committee approval.
The credit memo for a 5–15 location vet group needs to land four things explicitly. First, the consolidated EBITDA with normalised owner comp and rent — the diligence will recompute both, so the seller's number needs to anticipate the lender's adjustment. Second, the clinic-level same-store revenue trend and visit trend, separated, so the lender can see that revenue growth is real even though visits are down — the macro context (Encore Vet's 2025 review, 14 quarters of visit decline per Ackerman, ACT growth of 6–10% per year per iVET360 and KSM) makes this a defensible story when the founder names it explicitly and an undefendable story when the founder hides it. Third, the doctor-retention picture — DVM unemployment is at 0.7%, retention is the credit risk in the deal, and the lender will not move without a clear answer on how the doctor base is locked in. Fourth, the integration plan with explicit working-capital line items and a 13-week cash projection through the integration window.
Lender expectations for senior leverage on platform-grade groups have settled at 3.5–4.5x EBITDA for first-lien with regional banks and 4.5–5.5x total leverage from private credit, with tighter covenants and documentation than the bank market. Sub-platform groups — the bottom three quartiles of the 5–15 band — should expect 2.5–3.5x first-lien at most, with a meaningful equity component on every acquisition. The fractional CFO sets these expectations with the founder before the lender meeting, not in it.
07 When the engagement graduates out
Around 15 locations, the fractional engagement should be planning its own end. The work has shifted from operating-finance to capital-structure-and-exit, and the seat is moving from fractional to full-time CFO or to interim-CFO-into-sale. We tell groups at the start of every engagement: we are building toward graduating you out, not extending the retainer indefinitely. The work is finished when a small number of named things are true.
- The 13-week cash forecast is owned by the controller or ops director and the founder reviews it on Mondays, not builds it.
- The clinic-level operating P&L lands on the head doctor's screen on the same day for every clinic, and the head doctor is accountable for the six lines on it.
- The harmonised doctor compensation model is documented, with a written production definition, a true-up cadence, and an onboarding sheet that the ops director can walk a new hire through without the founder in the room.
- The next acquisition can be sized in an afternoon — not a quarter — against a documented credit memo template and a working-capital model that has been validated on the last two deals.
- The lender relationship is mature enough that the founder has had two consecutive years of clean covenant compliance and an actively-managed leverage ratio.
- The exit option is named — sale to consolidator in 18–36 months as a quasi-platform, sale as an add-on, or continued independent growth with a full-time CFO in seat. Whichever path the founder chooses, the next twelve months of finance work is defined.
In our sample of eleven engagements, the median graduation point has landed between months 14 and 20. Three engagements graduated to interim-CFO-into-sale (each closed a transaction inside six months of graduation, two as quasi-platforms at 10x+ EBITDA, one as an add-on at 7x). Four hired a full-time CFO and we transitioned the relationship to a quarterly advisory cadence. Two extended the fractional engagement at a reduced cadence as the group continued independent growth, with a re-evaluation conversation every twelve months. Two remain in the active engagement window. The point is that the seat has a defined endpoint, defined by operating capability inside the group, not by the calendar.
08 What this looks like as a working engagement
A typical fractional CFO engagement in this band runs 18–24 months at 8–12 hours per week of senior partner time plus a controller-level analyst in support. The first 90 days rebuild the cash visibility, the clinic-level operating P&L, and the doctor-comp framework. Months 4–9 are the working rhythm — weekly cash, monthly operating review, quarterly board pack, and one acquisition modeled, sized, and either signed or walked away from. Months 10–18 are usually one or two acquisitions plus the lender relationship build. Months 18–24 are the transition — either to a full-time CFO, into a sale process, or to a reduced-cadence advisory seat.
The pricing context behind the engagement is worth naming once more. The veterinary services market is structurally tight on the DVM side, structurally pressured on visit volume, and structurally favourable on ACT and pricing — which is exactly the operating profile where a finance seat that watches weekly cash, weekly clinic-level mix, and quarterly acquisition discipline pays back many multiples of its cost. The Q4 2025 RL Hulett pet sector update counts 436 deals in 2025 versus 377 in 2024, a 15.7% YoY increase — the consolidation market is active, the bidders are well-funded, and the discipline that surfaces a defensible normalised EBITDA is the single biggest determinant of where in the 6–9x add-on band or the 10–14x quasi-platform band a specific group lands. That work starts on the operating P&L, not in the diligence room.
Frequently asked questions
What does a fractional CFO actually do for a 5–15 location veterinary group?
Why does the founder lose cash visibility around the third or fourth clinic?
What EBITDA multiple should a 5–15 location veterinary group expect to transact at?
What are the operating benchmarks for a healthy small-animal veterinary clinic in 2024–2026?
How is the macro veterinary services environment affecting fractional CFO work?
How is doctor compensation typically structured in a consolidating veterinary group?
When does the fractional CFO engagement end, and what comes next?
Sample: 11 veterinary groups, 5–15 locations, U.S. and Canada, 2022–2026. Sale outcomes (3), full-time CFO transitions (4), continued retainers at reduced cadence (2), and active engagements (2) all represented.
Industry benchmarks: AVMA Economic State of the Veterinary Profession 2024; Mars Veterinary Health workforce models; Encore Vet 2025 In Review; Ackerman Group veterinary M&A and benchmark commentary 2024–2025; iVET360 Veterinary Industry Benchmark Report (2023, on 2022 data); KSM 2026 outlook for veterinary practices; Today's Veterinary Business / VHMA / Vetcelerator / PlotPath operating-finance benchmarks; Simmons & Associates and Transitions Elite M&A commentary; RL Hulett Pet M&A Q4 2025 update; Capstone Partners April 2026 Pet Sector M&A update; Serenity / Vetted 2026 valuation guide; Proskauer and Mandelbaum Barrett legal commentary 2024–2025.
BLS / wage data: U.S. Bureau of Labor Statistics Occupational Employment Statistics, veterinarian average salary 2025 (~$136,000).
Full source list at content-pipeline/research/fractional-cfo-pre-consolidator-vet-groups/sources.md in the Putra & Co content pipeline.
Filed under the Operating practice, multi-site healthcare cohort. Cross-reads at /blog/multi-site-healthcare-ma-multiples-q2-2026/, /blog/first-100-days-post-acquisition-multi-site-healthcare/, /blog/dso-day-1-to-100-integration-playbook/, /blog/13-week-cash-flow-template-dso-multi-site-medical/, and /blog/provider-productivity-dso-single-metric/.